Literature DB >> 11595837

Mechanisms of tamoxifen-induced apoptosis.

S Mandlekar1, A N Kong.   

Abstract

Tamoxifen (TAM) has been used in the treatment of breast cancer for over a decade. The observed clinical efficacy of TAM has been attributed to both growth arrest and induction of apoptosis within the breast cancer cells. Although the primary mechanism of action of TAM is believed to be through the inhibition of estrogen receptor (ER), research over the years has indicated that additional, non-ER-mediated mechanisms exist. These include modulation of signaling proteins such as protein kinase C (PKC), calmodulin, transforming growth factor-beta (TGFbeta), and the protooncogene c-myc. Recent studies, including those from our laboratory, have implicated the role of caspases and mitogen-activated protein kinases (MAPK), including c-Jun N-terminal kinase (JNK) and p38 in TAM-induced apoptotic signaling. Oxidative stress, mitochondrial permeability transition (MPT), ceramide generation as well as changes in cell membrane fluidity may also play important roles in TAM-induced apoptosis. These various signaling pathways underlying TAM-induced apoptosis will be reviewed in this article.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11595837     DOI: 10.1023/a:1012437607881

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  119 in total

1.  Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner.

Authors:  Stephanie J Byer; Jenell M Eckert; Nicole M Brossier; Buffie J Clodfelder-Miller; Amy N Turk; Andrew J Carroll; John C Kappes; Kurt R Zinn; Jeevan K Prasain; Steven L Carroll
Journal:  Neuro Oncol       Date:  2010-11-12       Impact factor: 12.300

2.  A novel synthetic C-1 analogue of 7-deoxypancratistatin induces apoptosis in p53 positive and negative human colorectal cancer cells by targeting the mitochondria: enhancement of activity by tamoxifen.

Authors:  Dennis Ma; Phillip Tremblay; Kevinjeet Mahngar; Pardis Akbari-Asl; Jonathan Collins; Tomas Hudlicky; James McNulty; Siyaram Pandey
Journal:  Invest New Drugs       Date:  2011-04-15       Impact factor: 3.850

3.  Fas binding to calmodulin regulates apoptosis in osteoclasts.

Authors:  Xiaojun Wu; Eun-Young Ahn; Margaret A McKenna; Hyeonju Yeo; Jay M McDonald
Journal:  J Biol Chem       Date:  2005-06-17       Impact factor: 5.157

4.  The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.

Authors:  Anjali Naresh; Ann D Thor; Susan M Edgerton; Kathleen C Torkko; Rakesh Kumar; Frank E Jones
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

5.  Delayed and persistent ERK1/2 activation is required for 4-hydroxytamoxifen-induced cell death.

Authors:  Jian-Hua Zhou; David V Yu; Jingwei Cheng; David J Shapiro
Journal:  Steroids       Date:  2007-07-07       Impact factor: 2.668

6.  Roles of volume-activated Cl- currents and regulatory volume decrease in the cell cycle and proliferation in nasopharyngeal carcinoma cells.

Authors:  L X Chen; L Y Zhu; T J C Jacob; L W Wang
Journal:  Cell Prolif       Date:  2007-04       Impact factor: 6.831

Review 7.  The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics.

Authors:  Tracy A Brooks; Laurence H Hurley
Journal:  Nat Rev Cancer       Date:  2009-11-12       Impact factor: 60.716

8.  Combinational treatment of gap junctional activator and tamoxifen in breast cancer cells.

Authors:  Gunjan Gakhar; Duy H Hua; Thu Annelise Nguyen
Journal:  Anticancer Drugs       Date:  2010-01       Impact factor: 2.248

9.  Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients.

Authors:  U Coskun; N Gunel; B Sancak; E Onuk; M Bayram; A Cihan
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

10.  Measurement of tamoxifen-induced apoptosis in glioblastoma by cytometric bead analysis of active caspase-3.

Authors:  Joy K Zartman; Nicholas K Foreman; Andrew M Donson; Julie M Fleitz
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.